Welcome to our dedicated page for Bicycle Therapeutics news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics stock.
Bicycle Therapeutics plc develops clinical-stage medicines based on its proprietary bicyclic peptide, or Bicycle®, technology. Its updates center on oncology programs using fully synthetic constrained peptides, including nuzefatide pevedotin, a Bicycle Drug Conjugate targeting EphA2; zelenectide pevedotin, a Bicycle Drug Conjugate targeting Nectin-4; BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist targeting Nectin-4 and CD137; and Bicycle Radioconjugates for radiopharmaceutical use.
Recurring news includes clinical and preclinical data presentations, oncology pipeline updates, financial results, leadership changes, and collaborations that support radioisotope and radiopharmaceutical supply. Company announcements also discuss work with partners in additional therapeutic areas and the structure of its U.K. and U.S. operations.
Bicycle Therapeutics reported recent business progress and first quarter 2024 financial results. The company showcased multiple preclinical and clinical abstracts at key industry meetings, highlighting the strength of its Bicycle® platform technology and pipeline. Key developments include the initiation of a Phase 2/3 clinical trial for BT8009 in metastatic urothelial cancer, significant progress across the R&D pipeline, and the promotion of Mike Hannay to Chief Product and Supply Chain Officer. With cash and cash equivalents of $457.0 million as of March 31, 2024, Bicycle Therapeutics is well-positioned for future growth and innovation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.